TIGIT and cancer: Notably, combining TLR agonists with immune checkpoint inhibitors such as PD-1/PD-L1, CTLA-4, TIGIT, and LAG3 has yielded synergistic effects and improved therapeutic outcomes across various cancer models [160,161,162].